Pfizer Announces Webcast Of April 6 Conference Call With Securities Analysts To Review Palbociclib Phase 2 Final Results

  Pfizer Announces Webcast Of April 6 Conference Call With Securities Analysts
  To Review Palbociclib Phase 2 Final Results Following Presentation At AACR
  Annual Meeting 2014

AACR Annual Meeting 2014

Business Wire

NEW YORK -- March 12, 2014

Pfizer Inc. invites investors and the general public to view and listen to a
webcast of a presentation by Pfizer’s Oncology leadership on Sunday, April 6,
2014 at 1:30 p.m. Pacific Daylight Time, in connection with the presentation
of the final results of the PALOMA-1 Phase 2 trial for palbociclib at the
American Association for Cancer Research (AACR) Annual Meeting 2014. There
will be a Q&A session following the presentation during the webcast.

This webcast is specifically tailored to the investment community. To view and
listen to the webcast, visit our website at www.pfizer.com and click on the
“Review of Palbociclib Phase 2  PALOMA-1 Results at AACR Annual Meeting 2014”
webcast link in the For Investors section located on the lower right-hand
corner of that page. Information on accessing and pre-registering for the
webcast will be available at www.pfizer.com beginning today. Participants are
advised to pre-register in advance of the conference call.

You can also listen to the conference call by dialing either (866) 246-2545 in
the United States and Canada or (706) 634-2365 outside of the United States
and Canada. The password is “AACR 2014”.

For medical and general questions about palbociclib, including information
about palbociclib clinical trials, please call 1-800-438-1985.

Visitors to www.pfizer.com will be able to view and listen to an archived copy
of the webcast of the conference call.

About PALOMA-1

PALOMA-1 (also known as Study 1003 and TRIO-18) is a Phase 2 trial designed to
assess the progression-free survival (PFS) of palbociclib (125 mg once daily
for three out of four weeks in repeated cycles) in combination with letrozole
versus letrozole alone (2.5 mg once daily on a continuous regimen) in
post-menopausal women with ER+, HER2- advanced breast cancer. PFS is comprised
of time from randomization to time of disease progression or death from any
cause. PALOMA-1 was conducted in collaboration with the Jonsson Cancer
Center’s Revlon/UCLA Women’s Cancer Research Program. PALOMA-1 is a
multi-center trial with 101 global sites participating.

Contact:

Media:
Sally Beatty, 212-733-6566
Investor:
Ryan Crowe, 212-733-8160
 
Press spacebar to pause and continue. Press esc to stop.